🔗 Share this article

An underground economy for unapproved weight-loss medications is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.

Experimental Drug Acquiring Popularity Via Social Media

The experimental drug, which is still in clinical trials, is being promoted by online personalities for its supposed weight-reducing properties. Followers are encouraged to message these profiles directly for supplier links, while also obtaining promotional offers.

Active Commerce on Social Networks

Additionally, a robust market exists on messaging services, where communities with numerous of participants share “before and after” images, injection guides and claims of next-day British shipping. Sellers market the substance there before redirecting customers to WhatsApp for purchases.

Learning About Retatrutide

Retatrutide is an experimental injection developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist patients reduce up to 25% of their total weight. Nicknamed the “triple G”, the substance is being hailed digitally as the next Ozempic.

Healthcare Professionals Voice Concerns

Nevertheless, physicians and chemists have warned that the sale of what remains an unlicensed medication in the UK is a cause for concern and could result in users administering substances of unknown origin.

Some professionals stated the popularity for the experimental drug could be connected to the rising price of licensed weight loss treatments such as Mounjaro.

Legal Position and Enforcement

Marketing the unapproved drug on TikTok or Telegram is illegal in the United Kingdom, as it is an unlicensed drug that must not be promoted or distributed for human use under the Human Medicines Regulations 2012.

Several influencers try to sidestep the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but advertising and distribution can still violate pharmaceutical, marketing, and consumer laws, risking penalties, prosecution or prison.

Service Response and Content Elimination

Based on the social media company, the service has removed violative material and prohibited related keywords and search suggestions. The organization said it was committed to maintaining the service secure and investing in enhancing compliance measures.

Digital Trading Operations

Investigations also found communities with up to 9,000 members marketing retatrutide using Telegram's built-in discovery tool, which functions like a online catalog. Entering “retatrutide” immediately displays groups with thousands of members, filled with images of slimming results, glowing reviews and detailed guides for preparing or injecting at home.

Within moments of joining one community, a seller shared WhatsApp details, where the majority of transactions take place. The vendor provided an guidebook and promised delivery within 48 hours. When questioned whether the product was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. Not one inquired about weight, health issues or past usage.

Item Information and Costs

Inside these communities, posts display black plastic parcels with Royal Mail stickers, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can select between powder vials, mixed at home with sterile water, or ready-to-use pens usually priced at £160 for 20 milligrams. When questioned how long a injector should last, vendors give conflicting responses ranging from a few weeks to “depends on your body”.

Platform Moderation and Security Measures

A spokesperson for Telegram said it regularly monitored dangerous content on its service including material that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“People are administering substances they cannot confirm. Although the research behind retatrutide is valid, these online products may not contain what they claim,” said Jason Murphy, the director of pharmaceutical services at Chemist4U.

A medical professional of Asda Online Doctor linked the surge in interest to recent price rises for approved slimming medications such as Mounjaro. “With prices increasing, individuals are using social media. But counterfeit treatments are highly dangerous. You cannot know what’s contained or whether the environment they were produced in was sterile,” she said.

Her staff has already encountered patients injured by self-injection from unverified suppliers. “We recognize the disappointment, but purchasing from messaging apps or communication platforms is taking chances with your health,” stated Wyllie. “These substances could be contaminated or incorrectly dosed.”

Producer Position

A spokesperson from Eli Lilly stated retatrutide was in third stage clinical trials and had not been reviewed or approved by any government authority globally. “Consequently at this time no one can market [it] for human use,” they said, noting that any product “falsely representing itself as a company investigational substance not yet authorized … may expose users to potentially significant medical dangers”.